Additionally, the 36-month beta value for AVDL is 1.52. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AVDL is 90.34M and currently, short sellers hold a 13.03% ratio of that float. The average trading volume of AVDL on September 11, 2024 was 1.28M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AVDL) stock’s latest price update
Avadel Pharmaceuticals plc (NASDAQ: AVDL)’s stock price has decreased by -4.22 compared to its previous closing price of 14.39. However, the company has seen a -6.36% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-03 that – Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –
AVDL’s Market Performance
Avadel Pharmaceuticals plc (AVDL) has experienced a -6.36% fall in stock performance for the past week, with a -13.85% drop in the past month, and a -9.74% drop in the past quarter. The volatility ratio for the week is 3.43%, and the volatility levels for the past 30 days are at 3.93% for AVDL. The simple moving average for the past 20 days is -10.82% for AVDL’s stock, with a -10.23% simple moving average for the past 200 days.
Analysts’ Opinion of AVDL
Many brokerage firms have already submitted their reports for AVDL stocks, with Rodman & Renshaw repeating the rating for AVDL by listing it as a “Buy.” The predicted price for AVDL in the upcoming period, according to Rodman & Renshaw is $27 based on the research report published on June 12, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see AVDL reach a price target of $29, previously predicting the price at $27. The rating they have provided for AVDL stocks is “Outperform” according to the report published on March 05th, 2024.
Needham gave a rating of “Buy” to AVDL, setting the target price at $22 in the report published on March 05th of the current year.
AVDL Trading at -12.60% from the 50-Day Moving Average
After a stumble in the market that brought AVDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.80% of loss for the given period.
Volatility was left at 3.93%, however, over the last 30 days, the volatility rate increased by 3.43%, as shares sank -15.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.62% lower at present.
During the last 5 trading sessions, AVDL fell by -6.59%, which changed the moving average for the period of 200-days by +20.30% in comparison to the 20-day moving average, which settled at $15.33. In addition, Avadel Pharmaceuticals plc saw -2.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVDL starting from MCHUGH THOMAS S, who purchase 2,000 shares at the price of $14.50 back on Jan 16 ’24. After this action, MCHUGH THOMAS S now owns 80,500 shares of Avadel Pharmaceuticals plc, valued at $29,000 using the latest closing price.
McCamish Mark Anthony, the Director of Avadel Pharmaceuticals plc, sale 75,000 shares at $14.53 during a trade that took place back on Dec 28 ’23, which means that McCamish Mark Anthony is holding 67,025 shares at $1,089,750 based on the most recent closing price.
Stock Fundamentals for AVDL
Current profitability levels for the company are sitting at:
- -1.04 for the present operating margin
- 0.95 for the gross margin
The net margin for Avadel Pharmaceuticals plc stands at -1.12. The total capital return value is set at -0.87. Equity return is now at value -99.52, with -59.26 for asset returns.
Based on Avadel Pharmaceuticals plc (AVDL), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -3.13. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is -10.25.
Currently, EBITDA for the company is -136.08 million with net debt to EBITDA at -0.09. When we switch over and look at the enterprise to sales, we see a ratio of 13.95. The receivables turnover for the company is 2.77for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.82.
Conclusion
In conclusion, Avadel Pharmaceuticals plc (AVDL) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
